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Recently, international regional differences in rates of mortality and morbidity in patients with chronic heart 
failure have been highlighted, as were the potential implica-
tions of these for the evaluation of the effects of treatments.1–5 
Specifically, in the Treatment of Preserved Cardiac Function 
with an Aldosterone Antagonist Trial (TOPCAT), the occur-
rence of the primary composite end point of cardiovascular 
death, hospitalization for heart failure, or resuscitation from 
cardiac arrest (which was a minor component) was much less 
common in patients from Russia or Georgia (unadjusted rate 
of 2.3 per 100 patient years in the placebo group) than in those 
enrolled in the United States, Canada, Argentina, or Brazil (“the 
Americas”, 12.6 per 100 patient years).5 This observation raises 
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States/Canada versus Eastern Europe/Russia persisted after adjustment for key prognostic variables: adjusted hazard ratios 
1.34 (95% confidence interval, 1.01–1.74; P=0.04) in I-Preserve and 1.85 (95% confidence interval, 1.17–2.91; P=0.01) in 
CHARM-Preserved. In HF-REF, rates of HF hospitalization were slightly lower in Western Europe compared with other 
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2 important questions. Firstly, was this a trial-specific concern 
in TOPCAT, or is it a more general issue in heart failure trials? 
Secondly, might this have been a problem specific to (or magni-
fied in) heart failure with preserved ejection fraction (HF-PEF), 
given the greater difficulty in defining this type of heart failure 
than heart failure with reduced ejection fraction (HF-REF)?6 To 
try and answer these questions, we have examined event rates in 
a number of other trials in both HF-PEF and HF-REF.7–11
Methods
We analyzed event rates of patients in the Irbesartan in Heart Failure with 
Preserved systolic function (I-Preserve), and in the Candesartan in Heart 
failure Assessment of Reduction in Mortality and morbidity (CHARM)-
preserved trials, the only other large trials in HF-PEF (in addition to 
TOPCAT) that included patients from both Europe and North America. 
We also analyzed the CHARM–Alternative and CHARM–Added tri-
als, as well as the Controlled Rosuvastatin Multinational Trial in HF 
(CORONA) trial, which enrolled patients with HF-REF. The design and 
principal findings of all of these trials have been reported.7–11
Patients
The CHARM program consisted of 3 trials comparing candesartan with 
placebo in subjects with symptomatic HF (New York Heart Association 
[NYHA] class II–IV). In the present analysis, we pooled the 2 CHARM 
HF-REF trials, which enrolled patients with a left ventricular ejection 
fraction (LVEF) ≤40%. The CHARM-Alternative trial enrolled subjects 
with intolerance of an angiotensin-converting enzyme inhibitor, and the 
CHARM-Added trial enrolled subjects who were treated with an angio-
tensin-converting enzyme inhibitor at baseline. The CHARM-Preserved 
trial enrolled subjects with LVEF >40%, all of which had a history of 
cardiovascular (CV) hospitalization. However, for the present analysis, we 
only included patients from CHARM-Preserved with a LVEF ≥45% so 
as to create a population similar to I-Preserve (see below). The primary 
end point used in the overall CHARM program was all-cause mortality, 
whereas that for each of the component trials was the composite of CV 
death or HF hospitalization. The median follow-up for the overall pro-
gram was 37.7 months. I-Preserve randomized subjects with HF-PEF to 
irbesartan or placebo. The inclusion criteria included LVEF ≥45%, age 
≥60 years, and NYHA class II through IV symptoms and hospitaliza-
tion for HF within the previous 6 months or NYHA class III through IV 
symptoms and ≥1 of an abnormal chest radiograph (pulmonary conges-
tion), ECG (left ventricular hypertrophy or left bundle-branch block), or 
echocardiogram (left ventricular hypertrophy or enlarged left atrium). The 
primary outcome used in the I-Preserve trial was a composite of all-cause 
mortality or CV hospitalization, and the mean follow-up was 49.5 months.
CORONA compared rosuvastatin with placebo in patients ≥60 
years of age with chronic HF-REF attributed to ischemic heart disease, 
who were in NYHA class II through IV, with a LVEF ≤40% (≤35% if 
NYHA II). The subjects enrolled were followed for a median of 32.8 
months, and the primary end point in the CORONA trial was a com-
posite of CV death, nonfatal myocardial infarction, or nonfatal stroke.
Region
For each trial, we grouped patients according to region: (1) Eastern 
Europe and Russia, (2) Western Europe, (3) United States and Canada 
(no patients in CORONA), and (4) Latin America (only patients from 
I-Preserve). The countries within each region from which patients 
were recruited varied slightly according to trial, and are listed in 
Table I in the online-only Data Supplement. Patients from South 
Africa (all trials), Australia, Malaysia, and Singapore (CHARM tri-
als) were excluded from the present analyses.
Clinical Outcome
In this analysis, we evaluated all-cause mortality, the composite end point 
of CV death and hospitalization for heart failure, as well as CV death and 
hospitalization for heart failure separately in each of the included trials. 
Maximal length of follow-up was 70 months in I-Preserve, 48 months in 
all 3 studies of the CHARM program, and 44 months in CORONA. All 
analyses were performed as time to first event. These end points were 
defined using similar prespecified criteria in each trial as part of either 
the original primary or a secondary end point. In each trial the end points 
were adjudicated by an independent end point validation committee. 
Confirmation of heart failure hospitalization required patients to have 
typical symptoms and signs and intensification of heart failure therapy on 
admission. In CHARM and CORONA, intravenous therapy was required 
whereas intensification of oral therapy was also acceptable in I-Preserve, 
although we believe few cases were confirmed on this basis.
Statistical Analysis
Baseline characteristics are presented as means with standard devia-
tions for continuous variables and frequencies and percentages for 
categorical variables. For all outcomes, patients lost to follow-up were 
censored at last day known to be alive, and for analyses of HF hos-
pitalization outcome, patients who died were censored. Unadjusted 
event rates were reported per 100 patient years of follow-up accord-
ing to recruitment region. Cox proportional hazard models were used 
to calculate hazard ratios for other regions compared with Eastern 
Europe/Russia, adjusting for age, sex, race (white versus all other 
race), heart rate, systolic blood pressure, body mass index, NYHA 
class, LVEF, ischemic etiology and history of diabetes, atrial fibril-
lation, stroke, and coronary revascularization. Some other potentially 
important predictive variables were not available in all trials (eg, his-
tory of heart failure hospitalization, creatinine, natriuretic peptides). 
Only predictive variables available in every trial were included in the 
adjusted model. Although the proportion of nonwhite participants 
in CORONA was low (0.4%), excluding race from the model for 
CORONA did not change the results. Therefore, race was left in the 
model for consistency. The assumptions of the Cox model (propor-
tional hazard, linearity of continuous variables, and no interactions) 
were tested and the models were found to be valid. We compared 
rates within each trial to avoid confounding regional differences with 
trial differences. Cumulative incidence curves were constructed for 
the composite of CV death and hospitalization for heart failure, as 
well as for all-cause mortality according to region for each trial.
N-terminal pro B-type natriuretic peptide (NT pro-BNP) levels were 
available in a subset of patients in I-Preserve (3418 patients, 542 who 
were hospitalized at least once for heart failure). In an ancillary analy-
sis, we adjusted the hazard ratio (HR) of heart failure hospitalization 
for baseline NT pro-BNP level, in addition to the variables mentioned 
above. All P values are 2-sided, and a P value of <0.05 was considered 
significant. All analyses were performed using Stata version 11 (Stata 
Corp. College Station, TX).
Results
Baseline Characteristics
The baseline characteristics of the patients enrolled in the tri-
als in HF-PEF and HF-REF are shown by region in Tables 1 
and 2 (HF-PEF) and Tables 3 and 4 (HF-REF).
HF-PEF Trials
By design, patients in I-Preserve (Table 1) were older than those 
in CHARM-Preserved (Table 2) and more likely to be in NYHA 
class III or IV. They were also more likely to be female and have 
a history of hypertension but less likely to have an ischemic etiol-
ogy. Patients in I-Preserve were more often treated with diuretics 
and mineralocorticoid receptor antagonists but less often treated 
with digoxin (despite a similar prevalence of atrial fibrillation). 
Within each trial, there were notable international geographic 
differences in baseline characteristics. For example, in CHARM-
Preserved ischemic etiology was much more common in Eastern 
Europe/Russia (and this was also true, but to a lesser extent, in 
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I-Preserve). Patients randomized in Eastern Europe/Russia were 
youngest in both trials. In I-Preserve, the proportion of women 
varied by region (from 51.4% in USA/Canada to 70.2% in Latin 
America); however, in both CHARM-Preserved and I-Preserve 
the proportion of women was greater in Eastern Europe/Russia 
than in Western Europe. Patients in Eastern Europe/Russia had 
a lower prevalence of atrial fibrillation than in Western Europe 
or North America in both trials (lowest of all in Latin America 
in I-Preserve). The prevalence of diabetes mellitus was high-
est in North America in both trials, as was history of coronary 
revascularization. NT pro-BNP and estimated glomerular filtra-
tion rate also varied substantially with the former highest and 
latter lowest in the United States/Canada in I-Preserve (NT pro-
BNP was not measured in CHARM-Preserved and estimated 
glomerular filtration rate was only measured in North American 
patients in CHARM-Preserved).
HF-REF Trials
By design, patients in CORONA (Table 3) were older than 
in CHARM Alternative/Added (Table 4), and all patients in 
Table 1. Baseline Characteristics of Patients in I-Preserve Overall and According to Region of Randomization
All Patients
Eastern Europe  
and Russia Western Europe
United States and
Canada Latin America P Value
I-Preserve 4080 1480 1499 385 716
Age, mean y 71.7±7.0 69.4±5.7 73.3±7.1 73.4±7.7 71.9±7.2 <0.0001
Female sex, n (%) 2461 (60.3%) 903 (61.0%) 855 (57.0%) 198 (51.4%) 505 (70.5%) <0.0001
Race, n (%) <0.0001
  White 3846 (94.3%) 1480 (100%) 1492 (99.5%) 348 (90.4%) 526 (73.5%)
  Black 73 (1.8%) 0 (0%) 2 (0.1%) 32 (8.3%) 39 (5.4%)
  Other 161 (3.9%) 0 (0%) 5 (0.3%) 5 (1.3%) 151 (21.1%)
Ejection fraction 0.59±0.09 0.58±0.08 0.60±0.10 0.59±0.08 0.60±0.09 <0.0001
NYHA class <0.0001
  I 1 (0%) 0 (0%) 0 (0%) 1 (0.3%) 0 (0%)
  II 868 (21.3%) 342 (23.1%) 370 (24.7%) 91 (23.6%) 65 (9.1%)
  III 3098 (75.9%) 1096 (74.1%) 1105 (73.7%) 285 (74.0%) 612 (85.5%)
  IV 112 (2.7%) 41 (2.8%) 24 (1.6%) 8 (2.1%) 39 (5.4%)
Heart rate, bpm 72±10 72±9 71±11 71±11 71±11 0.1402
Systolic blood pressure, 
mm Hg
136.4±15.0 137.1±12.2 137.6±16.3 131.6±17.9 134.9±15.0 <0.0001
Body mass index 29.6±5.3 29.2±4.4 29.3±5.1 32.5±7.3 29.6±5.5 <0.0001
NT pro-BNP, median
Q1–Q3
341
133–967
277
117–757
427
155–1086
633
224–1431
268
111–820
<0.0001
eGFR, −l/min/1.73m2 68.5±19.1 73.2±17.0 68.3±19.6 58.8±20.1 64.4±18.8 <0.0001
Ischemic etiology 1012 (24.8%) 479 (32.4%) 363 (24.2%) 92 (23.9%) 78 (10.9%) <0.0001
Hypertensive etiology 2608 (63.9%) 927 (62.6%) 875 (58.4%) 198 (51.4%) 608 (84.9%) <0.0001
Medical history, n (%)
  Hypertension 3610 (88.5%) 1374 (92.8%) 1226 (81.8%) 331 (86.0%) 679 (94.8%) <0.0001
  Atrial fibrillation 1206 (29.6%) 357 (24.1%) 553 (36.9%) 161 (41.8%) 135 (18.9%) <0.0001
  Diabetes mellitus 1115 (27.3%) 338 (22.8%) 434 (29.0%) 160 (41.6%) 183 (25.6%) <0.0001
  Stroke 396 (9.7%) 110 (7.4%) 169 (11.3%) 59 (15.3%) 58 (8.1%) <0.0001
  PCI or CABG 532 (13.0%) 51 (3.4%) 304 (20.3%) 139 (36.1%) 38 (5.3%) <0.0001
  ICD 12 (0.3%) 0 (0.0%) 7 (0.5%) 4 (1.0%) 1 (0.1%) 0.0033
  CRT/PM 252 (6.2%) 36 (2.4%) 137 (9.1%) 51 (13.2%) 28 (3.9%) <0.0001
Medication, n (%)
  Loop-diuretic 3382 (83.0%) 1380 (93.2%) 1151 (76.9%) 328 (85.4%) 523 (73.0%) <0.0001
  ACEi/ARB 1020 (25.0%) 350 (23.6%) 384 (25.7%) 107 (27.9%) 179 (25.0%) 0.3262
  β-Blocker 2394 (58.7%) 1033 (69.8%) 802 (53.6%) 244 (63.5%) 315 (44.0% <0.0001
  Mineralocorticoid 
receptor antagonist
630 (25.5%) 261 (17.6%) 239 (16.0%) 51 (13.3%) 79 (11.0%) 0.0005
  Digoxin 558 (13.7%) 195 (13.2%) 224 (15.0%) 51 (13.3%) 88 (12.3%) 0.3046
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CRT, cardiac resynchronization 
therapy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter defibrillator; I-Preserve, Irbesartan in Heart Failure with Preserved systolic function; NT 
pro-BNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and PM, pacemaker.
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CORONA had an ischemic etiology. Patients in CORONA 
were more likely than those in CHARM-Alternative/Added 
to have a history of hypertension, atrial fibrillation, and 
stroke (but less likely to have had coronary revasculariza-
tion). Patients in CORONA were more likely to be treated 
with an angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker (ARB) (by design), a β-blocker, and 
a mineralocorticoid receptor antagonist (but less likely to 
be treated with digoxin) than those in CHARM-Alternative/
Added. There were some international geographic differences 
within each trial. For example, patients in Eastern Europe/
Russia were younger than in other regions and more often 
female in both trials. The proportion of patients in NYHA 
class II was smallest in Eastern Europe/Russia in CORONA, 
a trend that was also seen in CHARM. Mean LVEF and sys-
tolic blood pressure was higher in Eastern Europe/Russia than 
in other regions. History of coronary revascularization was 
less common in Eastern Europe/Russia than in other regions 
in both trials. There were also differences between regions in 
drug therapy. Mineralocorticoid receptor antagonist use was 
highest in Eastern Europe/Russia and digoxin use lowest in 
Western Europe, in both trials. The median NT pro-BNP level 
was similar in Eastern Europe/Russia and Western Europe in 
CORONA, the only HF-REF trial in which it was measured.
Table 2. Baseline Characteristics of Patients in CHARM-Preserved Overall and According to Region of Randomization to Region of 
Randomization
All Patients Eastern Europe and Russia Western Europe
United States and
Canada P Value
CHARM-Preserved 2401 274 1174 953
Age, mean y 66.8±11.0 62.7±9.6 68.3±10.8 66.2±11.3 <0.0001
Female sex, n (%) 1021 (42.5%) 116 (42.3%) 479 (40.8%) 426 (44.7%) 0.1941
Race, n (%) <0.0001
  White 2254 (93.9%) 274 (100%) 1160 (100%) 820 (86.0%)
  Black 107 (4.5%) 0 (0%) 5 (0.4%) 102 (10.7%)
  Other 40 (1.7%) 0 (0%) 9 (0.8%) 31 (3.3%)
Ejection fraction 0.56±0.09 0.54±0.08 0.56±0.09 0.57±0.08 <0.0001
NYHA class <0.0001
  II 1483 (61.8%) 201 (73.4%) 822 (70.0%) 460 (48.3%)
  III 878 (36.6%) 71 (25.9%) 336 (28.6%) 471 (49.4%)
  IV 40 (1.7%) 2 (0.7%) 16 (1.4%) 22 (2.3%)
Heart rate, bpm 71±13 72±12 72±13 71±11 0.0437
Systolic blood pressure, 
mm Hg
136.6±18.7 136.0±17.4 139.1±19.3 133.7±17.7 <0.0001
Body mass index 29.3±5.9 28.5±4.6 28.0±4.6 31.2±7.0 <0.0001
eGFR, −l/min/1.73m2 72.4±25.5 … … 72.4±25.5 …
Ischemic etiology 1293 (53.9%) 200 (73.0%) 638 (54.3%) 469 (49.2%) <0.0001
Hypertensive etiology 589 (24.5%) 56 (20.4%) 282 (24.0%) 251 (26.3%) 0.1150
Medical history, n (%)
  Hypertension 1573 (65.5%) 199 (72.6%) 638 (54.3%) 736 (77.2%) <0.0001
  Atrial fibrillation 721 (30.0%) 54 (19.7%) 369 (31.4%) 298 (31.3%) 0.0004
  Diabetes mellitus 668 (27.8%) 59 (21.5%) 233 (19.8%) 376 (39.5%) <0.0001
  Stroke 206 (8.6%) 23 (8.4%) 89 (7.6%) 94 (9.9%) 0.1731
  PCI 421 (17.5%) 15 (5.5%) 211 (18.0%) 195 (20.5%) <0.0001
  CABG 497 (20.7%) 19 (6.9%) 218 (18.6%) 260 (27.3%) <0.0001
  ICD 17 (0.7%) 0 (0%) 7 (0.6%) 10 (1.0%) 0.1540
  CRT/PM 177 (7.4%) 19 (6.9%) 80 (6.8%) 78 (8.2%) 0.4646
Medication, n (%)
  Loop-diuretic 1789 (74.5%) 193 (70.4%) 810 (69.0%) 786 (82.5%) <0.0001
  ACEi/ARB 437 (18.2%) 18 (6.6%) 184 (15.7%) 235 (24.7%) <0.0001
  β-Blocker 1343 (55.9%) 180 (65.7%) 623 (53.1%) 540 (56.7%) 0.0006
  Mineralocorticoid 
receptor antagonist
279 (11.6%) 23 (8.4%) 160 (13.6%) 96 (10.1%) 0.0082
  Digoxin 641 (26.7%) 58 (21.2%) 275 (23.4%) 308 (32.3%) <0.0001
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CHARM-Preserved, Candesartan 
in Heart failure Assessment of Reduction in Mortality and morbidity Preserved; CRT, cardiac resynchronization therapy; eGFR, estimated glomular filtration rate; ICD, 
implantable cardioverter defibrillator; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and PM, pacemaker. 
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Clinical Outcomes
The rates of the clinical outcomes of interest, defined as the first 
in-trial event, are shown in Tables 5 and 6 and in Figures 1 and 2.
HF-PEF trials
Unadjusted Event Rates
The unadjusted rate of death from any cause (Table 5 and Figure 
I in the online-only Data Supplement) was higher in the United 
States/Canada and Western Europe compared with Eastern 
Europe/Russia in both CHARM-Preserved and I-Preserve 
(and in I-Preserve the all-cause mortality rate in Latin America 
was similar to Eastern Europe/Russia). The unadjusted rate of 
cardiovascular mortality was also higher in the United States/
Canada and Western Europe than in Eastern Europe/Russia in 
CHARM-Preserved, whereas rates were similar in I-Preserve.
The international geographic differences in rates of first 
heart failure hospitalization were much more striking. These 
were by far the highest in the United States/Canada and low-
est in Eastern Europe/Russia in both trials. The rate of heart 
failure hospitalization in Western Europe was intermediate but 
closer to Eastern Europe/Russia (and Latin America) than the 
United States/Canada.
The rate of the cardiovascular composite outcome reflected 
the geographic differences in its components.
Table 3. Baseline Characteristics of Patients in CORONA Overall and According to Region of Randomization
All Patients Eastern Europe and Russia Western Europe P Value
CORONA 4897 2384 2513
Age, mean y 72.8±7.1 71.1±6.6 74.3±7.1 <0.0001
Female sex, n (%) 1142 (23.3%) 605 (25.4%) 537 (21.4%) 0.0009
Race, n (%) <0.0001
  White 4870 (99.4%) 2383 (100%) 2487 (99.0%)
  Black 10 (0.2%) 1 (0.0%) 9 (0.4%)
  Other 17 (0.3%) 0 (0.0%) 17 (0.7%)
Ejection fraction 0.31±0.06 0.32±0.06 0.29±0.07 <0.0001
NYHA class <0.0001
  II 1810 (37.0%) 598 (25.1%) 1212 (48.2%)
  III 3015 (61.6%) 1755 (73.6%) 1260 (50.1%)
  IV 72 (1.5%) 31 (1.3%) 41 (1.6%)
Heart rate, bpm 72±11 73±11 70±11 <0.0001
Systolic blood pressure, mm Hg 129.4±16.3 130.4±14.4 128.4±17.9 <0.0001
Body mass index, units 27.2±4.5 27.7±4.5 26.7±4.5 <0.0001
NT pro-BNP, median
Q1–Q3, units
1431
609–3102
1421
568–2993
1437
631–3148
0.3375
eGFR, −l/min/1.73m2 54.5±14.6 57.2±13.8 52.0±14.9 <0.0001
Ischemic etiology 4897 (100%) 2384 (100%) 2513 (100%) …
Hypertensive etiology 0 0 0 …
Medical history, n (%)
  Hypertension 3092 (63.1%) 1833 (76.9%) 1259 (50.1%) <0.0001
  Atrial fibrillation 2023 (41.3%) 997 (41.8%) 1026 (40.8%) 0.4807
  Diabetes mellitus 1425 (29.1%) 778 (32.6%) 647 (25.7%) <0.0001
  Stroke 608 (12.4%) 315 (13.2%) 293 (11.7%) 0.0994
  PCI 565 (11.5%) 155 (6.5%) 410 (16.3%) <0.0001
  CABG 811 (18.2%) 253 (11.2%) 558 (25.4%) <0.0001
  ICD 135 (2.8%) 15 (0.6%) 120 (4.8%) <0.0001
  CRT/PM 553 (11.3%) 245 (10.3%) 308 (12.3%) 0.0287
Medication, n (%)
  Loop-diuretic 3694 (75.4%) 1754 (74.5%) 1940 (77.2%) 0.0032
  ACEi/ARB 4493 (91.8%) 2176 (91.3%) 2319 (92.2%) 0.2394
  β-Blocker 3644 (74.4%) 1859 (78.0%) 1785 (71.0%) <0.0001
  Mineralocorticoid receptor 
antagonist
1919 (39.2%) 1095 (45.9%) 824 (32.8%) <0.0001
  Digoxin 1619 (33.1%) 873 (36.6%) 746 (29.7%) <0.0001
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CORONA, Controlled Rosuvastatin 
Multinational Trial in HF; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; NT pro-BNP, N-terminal pro B-type natriuretic peptide; 
NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and PM, pacemaker. 
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Adjusted Hazard Ratios
After adjustment to take account of the differences in impor-
tant prognostic variables between patients in the different 
regions, the geographic variation in heart failure hospital-
ization persisted, remaining significantly greater in North 
America, compared with Eastern Europe/Russia in both tri-
als. In I-Preserve cardiovascular mortality (but not all-cause 
mortality) was lower in Western Europe than in Eastern 
Europe/Russia.
In a subset of patients in I-Preserve we also adjusted the 
rate of hospitalization for heart failure for baseline NT pro-
BNP level. After this additional adjustment the HR decreased 
to 1.02 (95% confidence interval [CI], 0.74–1.14), P=0.89.
HF-REF Trials
Unadjusted Rates
The unadjusted rate of death from any cause (and from cardio-
vascular causes) did not vary much by international geographic 
region in either CHARM Alternative/Added or CORONA 
(Table 6 and Figure II in the online-only Data Supplement), 
in contrast to the findings in HF-PEF. However, the rates of 
first heart failure hospitalization did vary by geographic region 
but not by as much as in HF-PEF or according to the same 
geographic pattern. In CHARM Alternative/Added, the rate of 
first hospitalization for heart failure was higher in the United 
States/Canada, compared with Eastern Europe/Russia and 
Western Europe. In CORONA (which was not conducted in the 
Table 4. Baseline Characteristics of Patients in CHARM-REF Overall and According to Region of Randomization
All Patients Eastern Europe and Russia Western Europe United States and Canada P Value
CHARM-Alternative+Added, n 4233 485 2117 1631
Age, mean y 64.8±11.0 62.7±10.9 65.5±10.4 64.7±11.6 <0.0001
Female sex, n (%) 1092 (25.8%) 135 (27.8%) 521 (24.6%) 436 (26.7%) 0.1869
Race, n (%) <0.0001
  White 3940 (93.1%) 484 (99.8%) 2076 (98.1%) 1380 (84.6%)
  Black 191 (4.5%) 0 (0.0%) 8 (0.4%) 183 (11.2%)
  Other 102 (2.4%) 1 (0.2%) 33 (1.6%) 68 (4.2%)
Ejection fraction 0.29±0.08 0.32±0.06 0.29±0.07 0.27±0.08 <0.0001
NYHA class, n (%) <0.0001
 II 1387 (32.8%) 138 (28.5%) 778 (36.8%) 471 (28.9%)
 III 2706 (63.9%) 324 (66.8%) 1272 (60.1%) 1110 (68.1%)
 IV 140 (3.3%) 23 (4.7%) 67 (3.2%) 50 (3.1%)
Heart rate, bpm 74±13 76±14 74±14 73±12 <0.0001
Systolic blood pressure, mm Hg 127.6±18.8 132.0±16.1 128.7±19.3 124.7±18.7 <0.0001
Body mass index, units 27.8±5.1 27.8±4.2 27.0±4.5 28.7±5.9 <0.0001
eGFR, −l/min/1.73m2 70.7±25.2 … … 70.7±25.2
Ischemic etiology 2733 (64.6%) 357 (73.6%) 1337 (63.2%) 1039 (63.7%) <0.0001
Hypertensive etiology 282 (6.7%) 42 (8.7%) 144 (6.8%) 96 (5.9%) 0.0926
Medical history, no. (%)
  Hypertension 2078 (49.1%) 291 (60.0%) 806 (38.1%) 981 (60.1%) <0.0001
  Atrial fibrillation 1132 (26.7%) 125 (25.8%) 566 (26.7%) 442 (27.1%) 0.7524
  Diabetes mellitus 1179 (27.9%) 136 (28.0%) 468 (22.1%) 575 (35.3%) <0.0001
  Stroke 365 (8.6%) 33 (6.8%) 160 (7.6%) 172 (10.5%) 0.0017
  PCI 663 (15.7%) 36 (7.4%) 298 (14.1%) 329 (20.2%) <0.0001
  CABG 1066 (25.2%) 57 (11.8%) 446 (21.1%) 563 (34.5%) <0.0001
  ICD 163 (3.9%) 1 (0.2%) 61 (2.9%) 101 (6.2%) <0.0001
  CRT/PM 400 (9.4%) 38 (7.8%) 167 (7.9%) 195 (12.0%) <0.0001
Medication, n (%)
  Loop-diuretic 3714 (87.7%) 425 (87.6%) 1831 (86.5%) 1458 (89.4%) 0.0270
  ACEi/ARB 2382 (56.3%) 234 (48.2%) 1194 (56.4%) 954 (58.5%) 0.0003
  β-Blocker 2364 (55.8%) 287 (59.2%) 1185 (56.0%) 892 (54.7%) 0.2146
  Mineralocorticoid receptor 
antagonist
822 (19.4%) 104 (21.4%) 420 (19.8%) 298 (18.3%) 0.2366
  Digoxin 2255 (53.3%) 240 (49.5%) 929 (43.9%) 1086 (66.6%) <0.0001
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CHARM-REF, -Alternative, +Added, 
Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Preserved, CHARM-Alternative, and CHARM–Added; CRT, cardiac resynchronization 
therapy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; 
and PM, pacemaker. 
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United States/Canada) the rate of first hospitalization for heart 
failure was higher in Eastern Europe/Russia than in Western 
Europe. As a consequence, the rate of the composite outcome 
in CHARM Alternative/Added was higher in the United States/
Canada than in Western Europe; in CORONA the rate was 
higher in Eastern Europe/Russia than in Western Europe.
Adjusted Hazard Ratios
There was no major variation in all-cause or cardiovascu-
lar mortality rates by international geographic region, and 
this was not changed after adjusting for other prognostic 
variables. After adjustment, the rate of heart failure hospi-
talization remained lower in Western Europe than in Eastern 
Europe/Russia in both trials. The adjusted hazard for each 
outcome of interest did not differ between the United 
States/Canada compared with Eastern Europe/Russia in the 
CHARM HF-REF trials.
Discussion
We found that rates of fatal and nonfatal events in patients 
with heart failure varied by international geographic region. 
However, this variation was notably greater for HF-PEF than 
for HF-REF and higher for heart failure hospitalization than 
for mortality. In 2 separate trials we found that unadjusted 
rates of both types of event in patients with HF-PEF were 
highest in the United States/Canada, intermediate in Western 
Europe, and lowest in Eastern Europe/Russia. In patients with 
HF-PEF, the difference in rates of heart failure hospitaliza-
tion persisted after adjustment for regional differences in key 
prognostic variables. In HF-REF we found little international 
geographic variation in mortality and a different geographic 
pattern of heart failure hospitalization rates. These rates were 
still highest in the United States/Canada (although these data 
were available from only 1 trial) but intermediate in Eastern 
Europe/Russia and lowest in Western Europe (ie, the pattern 
was reversed in Europe compared with HF-PEF).
Our study was stimulated by the findings of TOPCAT, and our 
results are consistent with those of TOPCAT.5 Indeed, the rate 
of the composite of cardiovascular death or heart failure hos-
pitalization in the United States/Canada in CHARM-Preserved 
(10.9 per 100 patient years) and I-Preserve (10.3 per 100 patient 
years) was similar to that for the primary composite outcome 
of cardiovascular death, heart failure hospitalization, or resusci-
tated cardiac arrest (with the last component adding few events) 
reported in the Americas in TOPCAT (12.6 per 100 patient 
years). Our rates of cardiovascular death or heart failure hospi-
talization in Eastern Europe/Russia (4.4 and 6.1 per 100 patient 
years in CHARM-Preserved and I-Preserve, respectively) were 
not, however, quite as low as that of the primary outcome in 
TOPCAT in Georgia/Russia (2.3 per 100 patient years).
Nevertheless, our findings in 2 separate trials, along with 
those of TOPCAT, suggest that the geographic differences in 
Table 5. Clinical Outcomes of Interest in HF-PEF Trials (CHARM-Preserved, I-Preserve) by Region
Region
Hazard Ratio (95% CI)
Eastern Europe 
and Russia Western Europe
United States  
and Canada Latin America
Western Europe vs Eastern  
Europe and Russia
United States and Canada vs  
Eastern Europe and Russia
Latin America vs Eastern  
Europe and Russia
CHARM-Preserved  
(EF ≥45%)
  No. of patients 274 1174 953 Unadjusted Adjusted* Unadjusted Adjusted* Unadjusted Adjusted*
  Event rates per 100 py 
(95% CI)
  All-cause mortality
   Cardiovascular 
death
  HF hospitalization
   HF hospitalization or 
cardiovascular death
3.2 (2.2–4.6)
2.1 (1.3–3.4)
2.8 (1.9–4.2)
4.4 (3.2–6.1)
5.4 (4.6–6.2)
3.6 (3.0–4.3)
4.7 (4.0–5.5)
6.9 (6.0–7.8)
5.5 (4.7–6.5)
3.7 (3.0–4.5)
8.8 (7.7–10.0)
10.9 (9.6–12.3)
1.69 (1.13–2.53)
P=0.01
1.69 (1.03–2.77)
P=0.04
1.66 (1.07–2.57)
P=0.02
1.53 (1.08–2.18)
P=0.02
1.20 (0.79–1.82)
P=0.40
1.22 (0.73–2.04)
P=0.45
1.22 (0.78–1.92)
P=0.39
1.14 (0.79–1.64)
P=0.49
1.75 (1.16–2.63)
P<0.01
1.74 (1.05–2.88)
P=0.03
2.99 (1.94–4.60)
P<0.01
2.38 (1.68–3.38)
P<0.01
1.28 (0.83–1.99)
P=0.27
1.29 (0.75–2.21)
P=0.35
1.85 (1.17–2.91)
P<0.01
1.55 (1.07–2.25)
P=0.02
I-Preserve
  No. of patients 1480 1499 385 716 Unadjusted Adjusted* Unadjusted Adjusted* Unadjusted Adjusted*
  Event rates per 100 py 
(95% CI)
   All-cause mortality
   Cardiovascular 
death
   HF hospitalization
   HF hospitalization 
or cardiovascular 
death
4.5 (4.0–5.1)
3.7 (3.2–4.2)
3.3 (2.9–3.9)
6.1 (5.5–6.8)
5.9 (5.3–6.5)
3.7 (3.2–4.2)
4.8 (4.2–5.4)
7.3 (6.7–8.1)
6.5 (5.4–7.9)
4.4 (3.5–5.6)
7.6 (6.3–9.3)
10.3 (8.7–12.2)
4.8 (4.1–5.7)
3.1 (2.5–3.8)
3.7 (3.1–4.5)
5.8 (5.0–6.8)
1.32 (1.13–1.55)
P<0.01
1.02 (0.85–1.23)
P=0.82
1.39 (1.15–1.68)
P<0.01
1.18 (1.02–1.36)
P=0.02
1.04 (0.88–1.24)
P=0.64
0.83 (0.68–1.02)
P=0.08
1.07 (0.87–1.31)
P=0.55
0.91 (0.78–1.06)
P=0.23
1.46 (1.16–1.83)
P<0.01
1.20 (0.92–1.57)
P=0.19
2.23 (1.75–2.83)
P<0.01
1.65 (1.36–2.01)
P<0.01
0.94 (0.73–1.22)
P=0.65
0.82 (0.60–1.12)
P=0.21
1.34 (1.01–1.77)
P=0.04
1.02 (0.82–1.28)
P=0.84
1.09 (0.89–1.33)
P=0.42
0.86 (0.67–1.09)
P=0.21
1.09 (0.86–1.39)
P=0.47
0.94 (0.78–1.13)
P=0.52
1.02 (0.81–1.29)
P=0.87
0.86 (0.65–1.13)
P=0.28
1.19 (0.91–1.56)
P=0.20
0.96 (0.77–1.18)
P=0.69
Rates of all-cause mortality, cardiovascular mortality, heart failure (HF) hospitalization, and the composite of cardiovascular mortality or HF hospitalization are given per 100 person-years (py) of follow-up. Hazard ratios 
are adjusted for age, sex, ischemic etiology, and history of diabetes mellitus, atrial fibrillation, and coronary revascularization. CHARM-Preserved indicates Candesartan in Heart failure Assessment of Reduction in Mortality 
and morbidity Preserved; CI, confidence interval; EF, ejection fraction; HF-PEF, heart failure with preserved EF; and I-Preserve, Irbesartan in Heart Failure with Preserved systolic function.
*Model adjusted for age, sex, race, heart rate, systolic blood pressure, body mass index, New York Heart Association class, ejection fraction, ischemic etiology, and history of diabetes mellitus, atrial fibrillation, stroke, 
and coronary revascularization.
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event rates appear to be particularly pronounced for HF-PEF 
and especially for heart failure hospitalization (the composite 
primary end point was not decomposed into its components 
in the primary results publication from TOPCAT). Moreover, 
although patient characteristics varied considerably by geo-
graphic region in HF-PEF, the geographic variation in the rate 
of heart failure hospitalization persisted after adjustment for 
other predictors of adverse outcomes.
We believe that the finding that the disparities were not 
as large in HF-REF and did not show the same regional pat-
tern raises more questions about international geographic 
variation in the diagnosis and management of patients with 
HF-PEF than about thresholds for hospital admission. The 
diagnosis of HF-PEF is more difficult than HF-REF. The 
symptoms and signs of heart failure are nonspecific and 
may have a noncardiovascular cause. For example, dyspnea 
and fatigue may be caused by advanced age, deconditioning, 
obesity, or hematologic and other comorbidities. Similarly, 
lower extremity edema may be caused by arthritis and venous 
insufficiency. A cardiac explanation for such symptoms and 
signs is made more likely by demonstration of left ventricular 
systolic dysfunction (ie, the patient probably has HF-REF). 
The diagnosis of HF-PEF, however, requires more advanced 
echocardiography techniques, invasive hemodynamic assess-
ments, or biomarker measurements, the availability of which 
likely vary geographically and the interpretation of which 
can be complex.6,12,13 Of interest in this respect, NT pro-BNP 
was measured at baseline in I-Preserve but the result was not 
made available to investigators (ie, it did not influence patient 
inclusion or exclusion in the trial). The median NT pro-BNP 
level varied by geographic region in a way that was consistent 
with the event rates (ie, was lowest in Eastern Europe/Russia 
and Latin America and highest in the United States/Canada). 
This calls into question the degree of cardiac dysfunction (or 
whether there was cardiac dysfunction at all) in patients in 
the low event-rate regions and raises the possibility of noncar-
diac causes of symptoms such as dyspnea and edema in these 
participants.14 In addition, when we adjusted for baseline NT 
pro-BNP level in I-Preserve, the international geographical 
difference in heart failure hospitalization rates was eliminated.
There are previous reports of international geographic 
variation in trials in patients with chronic HF-REF. The 
Table 6. Clinical Outcomes of Interest in HF-REF Trials (CHARM HF-REF Trials and CORONA) by Region
Region
Hazard Ratio (95% CI)
Eastern Europe and 
Russia Western Europe
United States and 
Canada
Western Europe vs Eastern Europe 
and Russia
United States and Canada vs Eastern 
Europe and Russia
CHARM- 
Alternative+Added
  No. of patients 485 2117 1631 Unadjusted Adjusted* Unadjusted Adjusted*
  Event rates per 100 
py (95% CI)
   All-cause 
mortality
   Cardiovascular 
death
   HF hospitalization
   HF hospitalization 
or cardiovascular 
death
10.5 (8.9–12.4)
8.5 (7.0–10.2)
9.9 (8.3–11.9)
15.2 (13.1–17.6)
10.4 (9.6–11.3)
8.7 (7.9–9.5)
8.7 (7.9–9.5)
14.1 (13.1–15.1)
10.2 (9.3–11.2)
8.4 (7.6–9.3)
12.1 (11.1–13.3)
17.2 (15.9–18.5)
0.99 (0.82–1.18)
P=0.89
1.03 (0.84–1.26)
P=0.78
0.89 (0.73–1.09)
P=0.25
0.94 (0.80–1.10)
P=0.44
0.88 (0.73–1.07)
P=0.20
0.93 (0.75–1.14)
P=0.47
0.78 (0.63–0.96)
P=0.02
0.84 (0.71–0.99)
P=0.04
0.97 (0.80–1.17)
P=0.75
0.99 (0.80–1.22)
P=0.93
1.21 (0.99–1.49)
P=0.06
1.12 (0.95–1.32)
P=0.17
0.81 (0.66–1.00)
P=0.05
0.83 (0.66–1.04)
P=0.11
0.90 (0.72–1.11)
P=0.33
0.89 (0.74–1.07)
P=0.21
CORONA
  No. of patients 2384 2513 Unadjusted Adjusted*
  Event rates per 100 
py (95% CI)
   All-cause 
mortality
   Cardiovascular 
death
   HF hospitalization
   HF hospitalization 
or cardiovascular 
death
11.3 (10.4–12.2)
9.4 (8.7–10.2)
12.9 (11.9–13.9)
19.1 (17.9–20.3)
12.4 (11.5–13.3)
9.3 (8.6–10.1)
10.7 (9.8–11.6)
16.6 (15.5–17.7)
1.10 (0.99–1.22)
P=0.08
0.98 (0.88–1.10)
P=0.77
0.83 (0.75–0.93)
P<0.01
0.87 (0.80–0.95)
P=0.01
0.96 (0.86–1.08)
P=0.54
0.86 (0.76–0.98)
P=0.03
0.80 (0.71–0.90)
P≤0.01
0.81 (0.74–0.90)
P<0.01
Rates of all-cause mortality, cardiovascular mortality, heart failure (HF) hospitalization, and the composite of cardiovascular mortality or HF hospitalization are given 
per 100 person-years (py) of follow-up. Hazard ratios are adjusted for age, sex, ischemic etiology, and history of diabetes mellitus, atrial fibrillation, and coronary 
revascularization. CHARM-Alternative+Added indicates Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Alternative and CHARM–Added; 
CI, confidence interval; CORONA, Controlled Rosuvastatin Multinational Trial in HF; and HF-REF, heart failure and reduced ejection fraction.
*Model adjusted for age, sex, race, heart rate, systolic blood pressure, body mass index, New York Heart Association class, ejection fraction, ischemic etiology, and 
history of diabetes mellitus, atrial fibrillation, stroke, and coronary revascularization.
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Assessment of Treatment with Lisinopril and Survival 
(ATLAS) trial investigators reported regional differences in 
baseline characteristics but did not report outcomes.15 The 
Metoprolol Controlled-Release Randomised Intervention 
Trial in Heart Failure trial (MERIT-HF) investigators pub-
lished a figure illustrating unadjusted all-cause mortality 
rates by country (rather than region).16 This trial included 
123 patients from the Czech Republic, 211 from Hungary, 
102 from Poland, and 532 from the United States. The mor-
tality rate was highest in the Czech Republic and lowest in 
the United States. Hospitalization rates were not reported. 
Rates of death (as opposed to proportion of deaths) have not 
been published for any other large trials in chronic HF-REF, 
as far as we are aware.
International geographic variation in short-term out-
comes was reported in the Placebo-Controlled Randomized 
Study of the Selective A(1) Adenosine Receptor Antagonist 
Rolofylline for Patients Hospitalized With Acute 
Decompensated Heart Failure and Volume Overload to 
Assess Treatment Effect on Congestion and Renal Function 
(PROTECT). In PROTECT, 60- and 180-day event rates 
were generally lowest in Russia and highest in North 
America, but this trial included relatively few patients and 
events within each region.17 The much larger Efficacy of 
Vasopressin Antagonism in Heart Failure: Outcome Study 
with Tolvaptan Program (EVEREST) also reported out-
comes in patients hospitalized with acute heart failure (and 
with a LVEF ≤40%) over a median follow-up of 9.9 months 
according to region of enrollment.18 Although crude death 
rates were highest in North America and lowest in Eastern 
Europe, the adjusted risk of death was significantly higher 
in South America (HR, 1.42; 95% CI, 1.15–1.76), relative to 
North America, and somewhat higher, but not significantly 
so, in Western Europe (HR, 1.16; 95% CI, 0.95–1.42) and 
Eastern Europe (HR, 1.17; 95% CI, 0.98–1.41). We did 
not find any regional difference in unadjusted or adjusted 
mortality rates in the 2 chronic HF-REF trials we were able 
to analyze, although we did not have patients from Latin 
America.
For the composite outcome of cardiovascular death or 
heart failure hospitalization, the HRs for South America, 
Western Europe, and Eastern Europe, relative to North 
America, were 1.11 (95% CI, 0.94–1.32), 1.10 (95% CI, 
0.93–1.28), and 0.84 (95% CI, 0.73–0.97), respectively. 
Rates of heart failure hospitalization were not reported 
separately, but the proportion of patients readmitted for 
heart failure was similar in all 3 regions. We too found a 
slightly but not significantly lower rate of this composite 
outcome in Eastern Europe compared with North America 
(in the CHARM HF-REF trials), but neither EVEREST nor 
the CHARM HF-REF trials showed the international geo-
graphic variation in heart failure hospitalization apparent in 
the HF-PEF trials.
Our findings are not about clinical practice but are, we 
believe, very relevant (along with the results of TOPCAT) 
to future trials in HF-PEF. Use of strict inclusion and 
exclusion criteria that incorporate measures of disease 
severity should reduce patient heterogeneity and lead to a 
more consistent risk of adverse outcomes across regions. 
Natriuretic peptides are the most obvious example of such a 
criterion/measure, and our findings in the subset of patients 
in I-Preserve with a baseline NT pro-BNP level strongly 
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Figure 2. Rates of all-cause mortality and heart failure (HF) 
hospitalization per 100 person-years (py) of follow-up in 
the Candesartan in Heart failure Assessment of Reduction 
in Mortality and morbidity-Alternative and CHARM–Added 
(CHARM-Alternative+Added) and Controlled Rosuvastatin 
Multinational Trial in HF (CORONA) trial by region: Eastern 
Europe/Russia (EE/R), Western Europe (WE), and United States/
Canada (USA/C).
Figure 1. Rates of all-cause mortality and heart failure (HF) 
hospitalization per 100 person-years (py) of follow-up in 
Candesartan in Heart failure Assessment of Reduction in 
Mortality and morbidity (CHARM)-Preserved and Irbesartan in 
Heart Failure with Preserved systolic function (I-Preserve) trials 
by region: Eastern Europe/Russia (EE/R), Western Europe (WE), 
and United States/Canada (USA/C).
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support their value in this respect. Clearly, some variation 
in mortality will remain, in part because of differences in 
noncardiovascular death rates (eg, from smoking-related 
lung disease and cancer) and cardiovascular death (related 
to differences in lifestyle and use of background disease-
modifying cardiovascular medications and devices), as 
well as possible differences in selection of patients, includ-
ing physician or patient willingness to enroll.19 Heart fail-
ure hospitalization rates may still vary more than mortality 
rates because these are more likely to be influenced by local 
health-care system organization and practice than is mor-
tality. However, this may be an unduly pessimistic perspec-
tive because, after adjustment, the regional differences in 
heart failure hospitalization rates in I-Preserve, which had 
more stringent inclusion criteria, were less marked than in 
CHARM-Preserved, which had less stringent enrollment 
criteria.
There were limitations to our study as with any report 
of this type. There are few trials in HF-PEF available for 
analysis. There are also few contemporary trials in chronic 
HF-REF with enrollment in all regions of interest (for 
example, the 2 most recent pharmacological trials and 2 
most recent device trials did not recruit in both Europe and 
North America).20–23 We may not have measured or fully 
adjusted for all important variables influencing fatal and 
nonfatal outcomes in heart failure. We analyzed data from 
clinical trials that enroll selected patients because of inclu-
sion and exclusion criteria, other patient factors (eg, abil-
ity and willingness to participate), and investigator factors 
(including financial incentives); therefore, extrapolation 
of our findings to clinical practice should be done with 
caution.
Regional rates of hospitalizations may also vary accord-
ing to cultural practices of physicians, thresholds for hos-
pitalizations, and access to health care, and we did not have 
information on management practices and health system 
approaches in every country and at every stage of heart 
failure.24
In summary, we found that rates of fatal and nonfatal 
events in patients with heart failure vary by international 
geographic region and that this variation is greater in those 
with HF-PEF, compared with HF-REF. Although this varia-
tion was attenuated by adjustment for regional differences 
in patient characteristics, it persisted, especially for heart 
failure hospitalization. Better definition of patients enrolled 
in trials in HF-PEF might reduce this variation and identify 
a population more likely to respond to effective heart failure 
treatments.
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CLINICAL PERSPECTIVE
In this study we examined international geographical variations in event rates in 5 large clinical trials in heart failure. We 
compared the rates of hospitalization for heart failure, all-cause, and cardiovascular death in Eastern Europe/Russia, with 
Western Europe and the United States/Canada. In patients with heart failure and preserved ejection fraction (HF-PEF) we 
found higher rates of heart failure hospitalization in the United States/Canada compared with Eastern Europe/Russia, but 
less difference for patients with heart failure and reduced ejection fraction (HF-REF). The observed differences in event rates 
suggests international geographic variation in 1 or more of the following: the definition and diagnosis of HF-PEF, the risk 
profile of patients enrolled, the threshold for heart failure hospitalization, or some other factor. This finding has implications 
for the conduct of future global trials in HF-PEF. Greater standardization of entry criteria and the baseline risk profile of 
patients may reduce such variation.
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Carson, Marc A. Pfeffer, Karl Swedberg, Hans Wedel, Salim Yusuf and John J. V. McMurray
McKelvie, Michael R. Zile, Christopher B. Granger, John Wikstrand, Michel Komajda, Peter E. 
Søren L. Kristensen, Lars Køber, Pardeep S. Jhund, Scott D. Solomon, John Kjekshus, Robert S.
Preserved and Reduced Ejection Fraction
International Geographic Variation in Event Rates in Trials of Heart Failure With
Print ISSN: 0009-7322. Online ISSN: 1524-4539 
Copyright © 2014 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation 
doi: 10.1161/CIRCULATIONAHA.114.012284
2015;131:43-53; originally published online November 18, 2014;Circulation. 
 http://circ.ahajournals.org/content/131/1/43
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://circ.ahajournals.org/content/suppl/2014/11/18/CIRCULATIONAHA.114.012284.DC1
Data Supplement (unedited) at:
  
 http://circ.ahajournals.org//subscriptions/
is online at: Circulation  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialCirculationin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 Supplemental Material 
 
Supplementary Table 1  Countries within each region according to trial  
 Eastern Europe and Russia Western Europe USA and Canada Latin America 
The CHARM Programme Czech Republic, Hungary, 
Poland, Russia. 
 
Belgium, Denmark, 
Finland, France, Germany, 
Iceland, Italy, Netherlands, 
Norway, Portugal, Spain, 
Sweden, Switzerland, 
UK/Ireland. 
Patients from both countries 
included. 
No patients   
CORONA Bulgaria, Czech Republic, 
Hungary, Poland, Romania, 
Russia, Slovakia 
 
Belgium, Denmark, 
Finland, France, Germany, 
Netherlands, Norway, 
Portugal, Spain, Sweden, 
Switzerland, UK/Ireland. 
No patients   No patients   
I-Preserve Czech Republic, Hungary, 
Poland, Russia 
 
Belgium, Denmark, France, 
Germany, Greece, Italy, 
Norway, Portugal, Spain, 
Sweden, Switzerland, 
Netherlands, UK/Ireland. 
Patients from both countries 
included. 
Argentina, Brazil, Mexico. 
 
Patients from Australia, Malaysia, Singapore (CHARM) and South Africa (all trials), were excluded.  
 
Supplementary Figure 1 
 
 
 
Supplementary Figure 2 
 
 
 
Figure legends: 
 
Supplementary Figure 1 Cumulative incidence of a composite of heart failure (HF) hospitalization or cardiovascular death, and all-cause mortality per 100 
person-years (py) of follow-up in CHARM-Preserved and I-Preserve by region: Eastern Europe/Russia (EE/R), Western Europe 
(WE) and United States of America/Canada (USA/C). 
Supplementary Figure 2  Cumulative incidence of a composite of heart failure (HF) hospitalization or cardiovascular death, and all-cause mortality per 100 
person-years (py) of follow-up in the CHARM HF-REF trials and CORONA by region: Eastern Europe/Russia (EE/R), Western 
Europe (WE) and United States of America/Canada (USA/C). 
 
